FDA Approves Eli Lilly's Mounjaro To Reduce Cardiovascular Risk In Type 2 Diabetes

FDA approval for Eli Lilly’s Mounjaro (tirzepatide) to lower the risk of major adverse cardiovascular events (MACE), including cardiovascular death and non-fatal heart attacks, is a major positive catalyst. The new indication strengthens the drug’s clinical and commercial outlook beyond diabetes, supporting upside for Lilly’s cardiovascular franchise and near-term investor sentiment.